Accelerate Diagnostics, Inc. (AXDX)

[mmillionaire]

This is what I learned by speaking with other AXDX shareholders who are knowledgeable about the science behind the company.
There are no competitor or comparisons in other 10K's because no one besides AXDX does BOTH rapid ID (molecular and phenotype) and AST (antibiotic susceptibility testing), which is the future "standard of care".
The current blood culturing technologies including all the FAST molecular tests by Cephaid, BD, Abbott and BioMuerio all KILL the bugs during ID. AXDX is the only test that keeps the bugs alive for AST testing. This is important because empiric therapy the current "standard of care" is wrong 37% of the time in determining the correct antibiotic drug to give the patient. The author of the misleading article touted Abbott Labs as having an edge in the area of rapid diagnosis. The largest shareholder of AXDX is former president of Abbot! Another criticism by the author of this article is the manner in which AXDX is doing initial testing. The reason AXDX is doing initial testing on blood culture bottles is that it is the fastest way to get FDA approval. Apparently the writer(s) of this article are clueless about this science.
For these reasons and many more, the National Institute of Health chose AXDX to receive a $5 million grant to study the antibiotic resistant SUPERBUG.